Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Q4 FY2006 Earnings Presentation
22 slides from Adams Respiratory Therapeutics's earnings presentation, Aug 24, 2006

Slide 1: Fiscal 2006 and Fiscal Fourth Quarter Earnings Conference Call
Adams Respiratory Therapeutics Fiscal 2006 and Fiscal Fourth Quarter Earnings Conference Call - August 24, 2006 Early 2006 Ending 2006

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

Slide 3: Fourth Quarter Financial Highlights
Fourth Quarter Financial Highlights Net sales increased 35% to $52.8 million Doubled pretax income to $11.0 million Income per diluted share increased to $0.17

Slide 4: Delsym Acquisition
Delsym(r) Acquisition Only 12-hour OTC cough liquid U.S. launch: December 1982 Unique Pennkinetic(r) technology 12-hour duration of action Superior taste masking Alcohol free Formulation patent (2017) Listed in FDA Orange Book 4 SKU's: 2 Adult/2 Children

Slide 5: Mucinex for Children
Mucinex(r) for Children Great-tasting* Precise dosing Offers base-brand end benefit: "Mucinex in...Mucus Out!"(tm) Source: Company sponsored research.

Slide 6: Production Capacity Improving
Production Capacity Improving Jan. 2006 Run Rate Q3 FY 06 Run Rate Current Run Rate Early CY 07 Run Rate $250 MM $400 MM $340 - $350 MM Includes existing facilities & equipment $100 MM $200 MM $300 MM $400 MM $500 MM $450+ MM Upon completion of several capital projects underway at Ft. Worth facility

Slide 7: FY 2006 Operating Highlights
FY 2006 Operating Highlights Secured guaifenesin supply, more than doubled manufacturing capacity Tripled our product portfolio from 2 to 6 items Nearly doubled Mucinex(r) brand awareness and market share in the cough/cold/allergy sinus category(1) Consumption up 50%(2) (1) Internal research (2) Acc

Slide 8: FY 2006 Operating Highlights
FY 2006 Operating Highlights Launched second season of award- winning Mucinex(r) advertising Granted 2nd patent from the U.S. PTO Ended fiscal year 2006 with about 220 Adams' employees* Improved our financial position *Excludes the approximately 300 employees added as of Aug. 1 with the repurchase o

Slide 9: Fiscal 2006 Financial Highlights
Fiscal 2006 Financial Highlights Net sales increased 49% to $239.1 million Pretax income increased 71% to $76.2 million SG&A expenses increased 27% to $99.0 million; conducted a $35 million consumer advertising campaign Development expenses increased 156% to $18.9 million(1) Income per diluted share

Slide 10: Fiscal 2006 Product Portfolio
$158.6 MM $59.2 MM $19.3 MM Launched 10/05 $1.3 MM Launched 3/06 Fiscal 2006 Product Portfolio Fiscal 2006 Net Sales increased 49% to $239.1 MM Platform technologies: Mucinex(r) and Humbid(r) franchises: extended release guaifenesin Delsym(r): Unique Pennkinetic(r) system with 12 hour duration of ac

Slide 11: Mucinex: Market Share Gains
Mucinex(r): Market Share Gains Source: Information Resources, Inc. (IRI)4, 12, and 52-week periods c/c/a/s category. $ Share

Slide 12: Fiscal 2006 Product Portfolio
$158.6 MM $59.2 MM $19.3 MM Launched 10/05 $1.3 MM Launched 3/06 Fiscal 2006 Product Portfolio Fiscal 2006 Net Sales increased 49% to $239.1 MM Platform technologies: Mucinex(r) and Humbid(r) franchises: extended release guaifenesin Delsym(r): Unique Pennkinetic(r) with 12 hour duration of action $0

Slide 13: Consumer Advertising and Line Extensions
Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? Repeat Success with Mucinex(r) Line Extensions Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $27 MM Rx market Consumer Advert

Slide 14: U.S. Development of Erdosteine
U.S. Development of Erdosteine 2005: In-licensed mucoregulator compound with a unique activity profile Full blown development project; investment of $50 - $60 million if ultimately successful Approved in > 30 foreign markets; ~24 million patient exposures Phase IIb clinical program underway (March 2

Slide 15: Adams' Strategy
Adams' Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Aggressively in-license/acquire new respiratory products Three - pronged strategy Drive Mucinex(r) brand awareness & market share through professionals and consumers

Slide 16: Adams' Performance Against The Strategy
Adams' Performance Against The Strategy Mucinex(r) Awareness & Market Share Growth: Achieved 68% consumer awareness in just two years (1) Achieved 97% (2) physician awareness with 64% (1) of users saying they got recommendation for Mucinex(r) from a healthcare professional Number 3 brand in the CCAS

Slide 17: Adams' Performance Against The Strategy: Internal Guaifenesin Pipeline
Adams' Performance Against The Strategy Building Internal Guaifenesin Pipeline: Mucinex(r) line extensions: DM launched in 2004; D launched in 2005; Children's products launched in 2006 Max.-strength products: Humibid(r) SE launched in 2006; D & DM to launch 2006E Development pipeline: 3 significant

Slide 18: Adams' Performance Against The Strategy: In-License/Acquire
Adams' Performance Against The Strategy In-License/Acquire New Respiratory Products: In-licensed erdosteine from Edmond Pharma in 2005 In-licensed proprietary Mini-Melt(tm) technology from Losan in 2006 Acquired Delsym(r) from UCB in June 2006 In-licensed Pennkinetic(r) technology from UCB June 2006

Slide 19: Adams' Strategy
Adams' Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Access platform technologies to accelerate product development Four - pronged strategy Drive Mucinex(r) brand awareness & market share among professionals and consumers Build Rx business

Slide 20: Financial Outlook: Income Statement Overview
Financial Outlook: Income Statement Overview Includes $16.1 million tax benefit related to the future benefit of NOLs. Includes $2.5 million after-tax impact of the discretionary performance bonus. $39.2 $52.8 $239.1 $160.2 $61.3 Net Sales 83.5% 79.7% 79.4% 80.6% 80.5% Gross Margin % $4.8 12% $11.0

Slide 21: Strong Growth in Revenues
2003 14 2004 61.3 2005 160.2 2006 239.1 2005 39.2 2006 52.8 2002 -15.5 2003 -22.6 2004 35.8 LTM 2003 8.9 2004 9.2 12- Months Ended 3- Months Ended Strong Growth in Revenues (in millions) 6/03 6/05 6/04 6/05 YoY Growth 35% CAGR '03-'05 158 % 6/06 6/06 $239.1 $39.2

Slide 22: Adams Respiratory Therapeutics
ADAMS RESPIRATORY THERAPEUTICS™ I\S
Source: SEC EDGAR · 8-K filed Aug 24, 2006
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Investor Presentation (April 2007)60 slides · Apr 4, 2007
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)21 slides · Feb 8, 2007